When subcloned into low-copy-number expression vectors, rumAB, encoding polV (RumA' B), is best characterized as a potent mutator giving rise to high levels of spontaneous mutagenesis in vivo. This is in dramatic contrast to the poorly mutable phenotype when polV is expressed from the native 88.5 kb R391, suggesting that R391 expresses cis-acting factors that suppress the expression and/or the activity of polV . Indeed, we recently discovered that SetR , an ortholog of λ cI repressor, is a transcriptional repressor of rumAB. Here, we report that CroS , an ortholog of λ Cro, also serves as a potent transcriptional repressor of rumAB. Levels of RumA are dependent upon an interplay between SetR and CroS , with the greatest reduction of RumA protein levels observed in the absence of SetR and the presence of CroS . Under these conditions, CroS completely abolishes the high levels of mutagenesis promoted by polV expressed from low-copy-number plasmids. Furthermore, deletion of croS on the native R391 results in a dramatic increase in mutagenesis, indicating that CroS plays a major role in suppressing polV mutagenesis in vivo. Inactivating mutations in CroS therefore have the distinct possibility of increasing cellular mutagenesis that could lead to the evolution of antibiotic resistance of pathogenic bacteria harboring R391.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460599PMC
http://dx.doi.org/10.1111/mmi.14777DOI Listing

Publication Analysis

Top Keywords

cros
8
cros ortholog
8
ortholog cro
8
plays major
8
major role
8
role suppressing
8
suppressing polv
8
high levels
8
mutagenesis vivo
8
polv expressed
8

Similar Publications

Targeted drugs have revolutionized the treatment of advanced non‑small cell lung cancer (NSCLC). However, the understanding of how cardiac comorbidity and toxicity affect the clinical outcomes of patients following targeted therapy remains limited. In a 14‑year cohort, cardiac comorbidities and toxicities among patients with stage‑IV NSCLC treated with targeted therapy were identified.

View Article and Find Full Text PDF

The human voltage-gated sodium channel Na1.5 (hNa1.5/SCN5A) plays a critical role in the initiation and propagation of action potentials in cardiac myocytes, and its modulation by various drugs has significant implications for cardiac safety.

View Article and Find Full Text PDF

Background: Fiji is a Pacific Island nation grappling with the increasing threat of antimicrobial resistance (AMR). While genomic technologies are increasingly utilised to understand the emergence and spread of AMR globally, its application to inform outbreak responses in low- and middle-income settings has not been reported.

Methods: Through an established capacity building program, suspected carbapenem-resistant organisms (CRO) identified at Colonial War Memorial Hospital in Fiji (Jan 2022-Oct 2023) underwent whole genome sequencing and analysis.

View Article and Find Full Text PDF

Setting: Papua New Guinea is a high-burden multidrug-resistant TB (MDR/RR-TB) country that reports low rates of bacteriological confirmation. Sputum drug susceptibility testing for second-line drugs is important. Access to culture is limited.

View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted on patients who had surgery for high-risk intraductal papillary mucinous neoplasms (IPMNs) that included a mural module, focusing on the relationship between dysplasia grade and the mural module location.
  • The research involved 82 patients, revealing that nearly half had high-grade dysplasia or invasive carcinoma away from the mural module, indicating that local treatment might not be safe or effective.
  • The results suggest that pancreatectomy (removal of part or all of the pancreas) remains the best treatment option due to the potential risks associated with localized treatments.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!